Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 12, 2025 in Berlin, Germany.

The company and its collaborators' commitment to advancing next-generation therapies for liver and viral diseases is reflected in these presentations, with topics spanning novel approaches, molecular strategies, insights into the mechanisms of action of ALG-000184, as well as a new strategy to potentially cure hepatitis delta virus (HDV) infection utilizing a proprietary antisense oligonucleotide (ASO) approach.

"We are pleased to present six preclinical presentations at the International HBV Meeting, that showcase our continued innovation in liver and viral diseases. With the Phase 2 B-Supreme study progressing nicely, we are pleased to present, for the first time, the direct effects of ALG-000184 in reducing HBV cccDNA in a preclinical setting. These data help corroborate the clinical observations of HBV antigen reductions seen in patients with chronic HBV infection treated with ALG-000184 monotherapy to date and are a direct indication that ALG-000184 can invoke the secondary mechanism of CAM-Es," stated Lawrence Blatt, PhD, MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "While we remain committed to the continued development of our best/first-in-class CAM-E ALG-000184 for chronic HBV infection, we are pleased to broaden our pipeline with the presentation of our discovery stage ASO program for the treatment of HDV. HDV coinfection with HBV leads to more rapid disease progression and our ASO uniquely targets the destruction of the viral genome, making this mechanism uniquely suited towards a potential HDV cure. Ongoing work will be aimed at selection of the HDV-targeted ASO clinical development candidate."

Details on the presentations are as follows:

Paper #: 52
Type: Oral Presentation
Title: The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments
Presenter: Yannick Debing, PhD
Date/Time: September 11, 2025 at 10:30am – 12:00pm CET
Session: Session X: Therapy II

Paper #: 53
Type: Oral Presentation
Title: Antisense oligonucleotide-based strategy to target hepatitis delta virus infections
Presenter: Julie Lucifora, PhD, CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon
Date/Time: September 11, 2025 at 10:30am – 12:00pm CET
Session: Session X: Therapy II

Paper #: 2
Type: Oral Presentation
Title: A Syrian hamster model of persistent HDV infection
Presenter: Elias Broeckhoven, KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute; Virology, Antiviral Drug and Vaccine Research Group; Laboratory of Molecular Vaccinology & Vaccine Discovery (MVVD)
Date/Time: September 8, 2025 at 5:00pm – 6:30pm CET
Session: Molecular Virology I

Paper #: 283
Type: Poster Presentation
Title: Differential impact of CAM-E and CAM-A on hepatitis B core protein phosphorylation states in vitro
Presenter: Hannah Vanrusselt
Date/Time: September 10, 2025 at 11:00am – 12:00pm CET
Session: Poster Session II

Paper #: 285
Type: Poster Presentation
Title: Capsid assembly modulators bind and directly target HBeAg
Presenter: Jordi Verheyen
Date/Time: September 10, 2025 at 11:00am – 12:00pm CET
Session: Poster Session II

Paper #: 127
Type: Poster Presentation
Title: PML nuclear bodies store aggregated HBc and reduce CAM-induced apoptosis in HBc-expressing cells
Presenter: Vaclav Janovec, PhD, University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
Date/Time: September 8, 2025 at 5:00pm – 6:30pm CET
Session: Molecular Virology

The presentations can be found on the Posters & Presentations section of the Aligos website ( www.aligos.com ) after the live event.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation, statements regarding Aligos' financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos' clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos' capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inizioevoke.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ALGS
The Conversation (0)
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress

Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress

- Data showcases sustained clinical benefit following seven years of LIVMARLI treatment in patients with Alagille syndrome - Long-term extension data from LIVMARLI PFIC studies highlight improvement in key liver markers and growth Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that... Keep Reading...
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the... Keep Reading...
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI®  Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

Positive opinion from CHMP based on Phase 3 MARCH study with highly statistically significant (p CHMP assessment concluded that LIVMARLI in PFIC brings significant clinical benefit over the existing approved therapy. Additionally, LIVMARLI received favorable COMP opinion recommending maintenance... Keep Reading...
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

- Data showcases sustained clinical benefit following 7 years of LIVMARLI treatment in patients with Alagille syndrome - Long-term extension data from LIVMARLI PFIC studies highlight improvement in key liver markers and growth Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that new... Keep Reading...
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two Top... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Latest Press Releases

Related News